- Conditions
- Lymphoma
- Interventions
- Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 32
- States / cities
- Gilbert, Arizona • Campbell, California • Duarte, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–19
of 19
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- PAH
- Interventions
- 75mg CXA-10, 150mg CXA-10, Placebo
- Drug · Other
- Lead sponsor
- Complexa, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan, Placebo, Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo
- Drug · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 28
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 23 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
- Biological
- Lead sponsor
- Keros Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
- Interventions
- Ralinepag, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- PAH
- Interventions
- CXA-10
- Drug
- Lead sponsor
- Complexa, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Background PAH Therapy
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more
- Conditions
- Alzheimer's Disease
- Interventions
- RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Anaheim, California • Fullerton, California • Lomita, California + 36 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 815 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 29 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Ibrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide, Vincristine, Idarubicin, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 14 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo, Sildenafil
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Columbus, Ohio • Providence, Rhode Island
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Background PAH Therapy
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
- Conditions
- Bone Pain in Stage I - III Breast Cancer
- Interventions
- Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 83
- States / cities
- Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- HS235, Placebo
- Biological · Other
- Lead sponsor
- 35Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo
- Drug · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo, Background PAH Therapy
- Biological · Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more